{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:23:08Z","timestamp":1793186588127,"version":"4.5.0"},"reference-count":68,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p> Dementia with Lewy bodies (DLB) is a clinical diagnosis representing a specific presentation of a pathological \u03b1-synucleinopathy (Lewy body disease). DLB is one entity under the broader term Lewy body dementia, which also includes Parkinson\u2019s disease dementia. Recent advances in DLB include publication of updated diagnostic criteria and recognition of prodromal DLB states, including mild cognitive impairment, delirium-onset, and psychiatric-onset forms. Research criteria for the mild cognitive impairment form of DLB were published in 2020. Increasing research shows that concomitant Alzheimer\u2019s disease pathology in individuals with DLB is common in addition to the \u03b1-synucleinopathy pathology. This has implications for biomarker use and expected progression. Identifying biomarkers for DLB is an area of active research. Cerebrospinal fluid and skin biopsy tests are now commercially available in the United States, but their role in routine clinical care is not yet established. Additional research and biomarkers are needed. Research suggests that median survival after DLB diagnosis is 3\u20134 years, but there are rapidly and slowly progressive forms. Most individuals with DLB die of complications of the disease. Clinical trials for individuals with DLB have increased over the last 5 years, targeting both symptoms and underlying pathology. Effective therapies remain an unmet need, however. This review focuses on recent advances with an emphasis on literature that informs clinical care. <\/jats:p>","DOI":"10.1177\/17562864211057666","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T10:52:49Z","timestamp":1637664769000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":36,"title":["Advances in dementia with Lewy bodies"],"prefix":"10.1177","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-1907","authenticated-orcid":false,"given":"Melissa J.","family":"Armstrong","sequence":"first","affiliation":[{"name":"Department of Neurology, College of Medicine, University of Florida, P.O. Box 100268, Gainesville, FL 32611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"bibr1-17562864211057666","first-page":"1113","volume-title":"Neurology","volume":"47","author":"McKeith IG","year":"1996"},{"key":"bibr2-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200210000-00001"},{"key":"bibr3-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.04.002"},{"key":"bibr4-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.1.1"},{"key":"bibr5-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13028"},{"key":"bibr6-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004058"},{"key":"bibr7-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"bibr8-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25844"},{"key":"bibr9-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"bibr10-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26796"},{"key":"bibr11-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26721"},{"key":"bibr12-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4609"},{"key":"bibr13-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2010.03.007"},{"key":"bibr14-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu143"},{"key":"bibr15-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000414"},{"key":"bibr16-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02255-2"},{"key":"bibr17-17562864211057666","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0460.1000444"},{"key":"bibr18-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009763"},{"key":"bibr19-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2017.09.014"},{"key":"bibr20-17562864211057666","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210272"},{"key":"bibr21-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2018.09.008"},{"key":"bibr22-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.4243"},{"key":"bibr23-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000436942.55281.47"},{"key":"bibr24-17562864211057666","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-161089"},{"key":"bibr25-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1159\/000441184"},{"key":"bibr26-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009323"},{"key":"bibr27-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2001.113989"},{"key":"bibr28-17562864211057666","unstructured":"Schneider J, Jeon S, Gladman JT, et al ADRD summit 2019 report to the National Advisory Neurological Disorders and Stroke Council. In: Alzheimer\u2019s disease-related dementias summit, 14\u201315 March 2019. Bethesda, MD: National Institutes of Health, https:\/\/www.ninds.nih.gov\/sites\/default\/files\/2019_adrd_summit_recommendations_508c.pdf (accessed 13 September 2021)."},{"key":"bibr29-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239279"},{"key":"bibr30-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000958"},{"key":"bibr31-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003512"},{"key":"bibr32-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008818"},{"key":"bibr33-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010943"},{"key":"bibr34-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005166"},{"key":"bibr35-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26668"},{"key":"bibr36-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.50897"},{"key":"bibr37-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-021-01175-w"},{"key":"bibr38-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012438"},{"key":"bibr39-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1159\/000329763"},{"key":"bibr40-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/alz.044409"},{"key":"bibr41-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004146"},{"key":"bibr42-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28242"},{"key":"bibr43-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.3311"},{"key":"bibr44-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28399"},{"key":"bibr45-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28651"},{"key":"bibr46-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011935"},{"key":"bibr47-17562864211057666","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10090616"},{"key":"bibr48-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.01.005"},{"key":"bibr49-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15608"},{"key":"bibr50-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202044"},{"key":"bibr51-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/gps.5462"},{"key":"bibr52-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1412652"},{"key":"bibr53-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047554"},{"key":"bibr54-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27360"},{"key":"bibr55-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3517"},{"key":"bibr56-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30153-X"},{"key":"bibr57-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034634"},{"key":"bibr58-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.12.005"},{"key":"bibr59-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"bibr60-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.07.005"},{"key":"bibr61-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1159\/000471507"},{"key":"bibr62-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.5157"},{"key":"bibr63-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.4200"},{"key":"bibr64-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.4725"},{"key":"bibr65-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1002\/alz.042589"},{"key":"bibr66-17562864211057666","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf3934"},{"key":"bibr67-17562864211057666","first-page":"e12171","volume":"7","author":"Lang FM","year":"2021","journal-title":"Alzheimers Dement"},{"key":"bibr68-17562864211057666","unstructured":"EIP Pharma. EIP Pharma announces positive phase 2 results for neflamapimod in mild-to-moderate dementia with Lewy bodies, https:\/\/www.eippharma.com\/news\/eip-pharma-announces-positive-phase-2-results-for-neflamapimod-in-mild-to-moderate-dementia-with-lewy-bodies-dlb\/ (2020, accessed 13 September 2021)."}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864211057666","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864211057666","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864211057666","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:58:53Z","timestamp":1740790733000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864211057666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":68,"alternative-id":["10.1177\/17562864211057666"],"URL":"https:\/\/doi.org\/10.1177\/17562864211057666","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17562864211057666"}}